Conversion between bromcresol green- and bromcresol purple-measured albumin in renal disease

被引:84
作者
Clase, CM
St Pierre, MW
Churchill, DN
机构
[1] Dalhousie Univ, Div Nephrol, Halifax, NS, Canada
[2] St Josephs Hosp, Dept Clin Chem, Hamilton, ON, Canada
[3] McMaster Univ, Div Nephrol, Hamilton, ON, Canada
关键词
albumin; bromcresol green; bromcresol purple; conversion; immunonephelometry; measurements;
D O I
10.1093/ndt/16.9.1925
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Albumin measured by a bromcresol purple dye-binding assay (Alb(BCP)) agrees more closely with the gold standard of immunonephelometry than does bromcresol green (Alb(BCG)) measurement. Both tests are in current clinical use. A method for converting between the two would be useful. Methods. We measured albumin by bromcresol green and bromcresol purple in 535 patients, 155 of whom had renal disease. We randomly divided data from the patients with renal disease into two equal-sized sets, and used one set to derive, and the remaining set to validate, a regression equation relating the two values. Results. The relationship Alb(BCG) = 5.5 + Alb(BCP) performed very well in both the renal patient validation set and in the data from 380 unselected in-patients and out-patients. Intraclass correlations for agreement between measured AlbBCG and predicted AlbBCG was 0.98 in both analyses. Conclusions. The ability to convert between these measurements will be of use in clinical situations where the absolute value of the serum albumin is important, when data from laboratories using different methodologies must be combined, and in the application of the Modification of Diet in Renal Disease formula to estimate glomerular filtration rate in patients whose albumin has been measured by bromcresol purple.
引用
收藏
页码:1925 / 1929
页数:5
相关论文
共 25 条
  • [1] BEYER C, 1994, CLIN CHEM, V40, P844
  • [2] SERUM-ALBUMIN CONCENTRATION-RELATED HEALTH-CARE FINANCING ADMINISTRATION QUALITY ASSURANCE CRITERION IS METHOD-DEPENDENT - REVISION IS NECESSARY
    BLAGG, CR
    LIEDTKE, RJ
    BATJER, JD
    RACOOSIN, B
    SAWYER, TK
    WICK, MJ
    LAWSON, L
    WILKENS, K
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (02) : 138 - 144
  • [3] BLAKE PG, 1993, J AM SOC NEPHROL, V3, P1501
  • [4] BUSH V, 1987, CLIN CHEM, V33, P821
  • [5] Albumin as an outcome measure in haemodialysis in patients: the effect of variation in assay method
    Carfray, A
    Patel, K
    Whitaker, P
    Garrick, P
    Griffiths, GJ
    Warwick, GL
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (11) : 1819 - 1822
  • [6] CANADIAN HEMODIALYSIS MORBIDITY STUDY
    CHURCHILL, DN
    TAYLOR, DW
    COOK, RJ
    LAPLANTE, P
    BARRE, P
    CARTIER, P
    FAY, WP
    GOLDSTEIN, MB
    JINDAL, K
    MANDIN, H
    MCKENZIE, JK
    MUIRHEAD, N
    PARFREY, PS
    POSEN, GA
    SLAUGHTER, D
    ULAN, RA
    WERB, R
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 19 (03) : 214 - 234
  • [7] Churchill DN, 1996, J AM SOC NEPHROL, V7, P198
  • [8] CORCORAN RM, 1977, CLIN CHEM, V23, P765
  • [9] DUGGAN J, 1982, CLIN CHEM, V28, P1407
  • [10] Foley RN, 1996, J AM SOC NEPHROL, V7, P728